Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Total Liabilities (2020 - 2025)

Barinthus Biotherapeutics' Total Liabilities history spans 6 years, with the latest figure at $23.9 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 20.92% year-over-year to $23.9 million; the TTM value through Dec 2025 reached $23.9 million, down 20.92%, while the annual FY2025 figure was $23.9 million, 20.92% down from the prior year.
  • Total Liabilities reached $23.9 million in Q4 2025 per BRNS's latest filing, down from $24.6 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $34.4 million in Q3 2023 to a low of $9.9 million in Q2 2021.
  • Average Total Liabilities over 5 years is $26.1 million, with a median of $27.8 million recorded in 2021.
  • Peak YoY movement for Total Liabilities: plummeted 66.05% in 2021, then soared 227.08% in 2022.
  • A 5-year view of Total Liabilities shows it stood at $28.2 million in 2021, then fell by 4.08% to $27.0 million in 2022, then grew by 1.88% to $27.5 million in 2023, then rose by 9.75% to $30.2 million in 2024, then dropped by 20.92% to $23.9 million in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Total Liabilities are $23.9 million (Q4 2025), $24.6 million (Q3 2025), and $27.1 million (Q2 2025).